TGTX climbs as Wall Street anticipates strong earnings growth following a recent rebound from earlier losses.
TG Therapeutics (TGTX) has been named a top growth stock in the IBD 50, driving its shares higher on Monday. The biotech firm, specializing in multiple sclerosis treatments, is recovering from a sharp decline earlier this month, with analysts forecasting significant earnings growth in upcoming quarters.
The stock holds the fourth position in the IBD 50, trailing Travere Therapeutics (TVTX), Eton Pharmaceuticals (ETON), and another peer. Recent earnings reports from biotech firms, including TGTX, have shown mixed performance, contributing to volatility in the sector.
Investor sentiment has improved as TGTX outperforms 95% of stocks, reflecting renewed confidence in its growth trajectory.